Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types

Bae, Seulgi; Ma, Kyungwan; Kim, Tae Hyung; Lee, Eun Seong; Oh, Kyung Taek; Park, Eun-Seok; Lee, Kang Choon; Youn, Yu Seok

doi:10.1016/j.biomaterials.2011.10.050

Cited by 215 publications

(147 citation statements)

References 39 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…24,25 Briefly, monomethoxypolyethylene glycol aldehyde (mPEG-ALD; molecular weight [Mw]: 5,000 Da) was purchased from the NOF Corporation (Tokyo, Japan). PLGA (Mw: 10,000 Da; lactic acid:glycolic acid ratio =50:50) was purchased from Wako Pure Chemical (Tokyo, Japan).…”

Section: Methodsmentioning

confidence: 99%

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Byeon

Kim

Choi

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

The aim of the current study was to investigate the antitumor potential of poly (D,L-lactic- co -glycolic acid) microspheres (PLGA MSs) containing polyethylene glycol (PEG)-conjugated (PEGylated) tumor necrosis factor–related apoptosis-inducing ligand (PEG-TRAIL). PEG-TRAIL PLGA MSs were prepared by using a water-in-oil-in-water double-emulsion method, and the apoptotic activities of supernatants released from the PLGA MSs at days 1, 3, and 7 were examined. The antitumor effect caused by PEG-TRAIL PLGA MSs was evaluated in pancreatic Mia Paca-2 cell-xenografted mice. PEG-TRAIL PLGA MS was found to be spherical and 14.4±1.06 μm in size, and its encapsulation efficiency was significantly greater than that of TRAIL MS (85.7%±4.1% vs 43.3%±10.9%, respectively). The PLGA MS gradually released PEG-TRAIL for 14 days, and the released PEG-TRAIL was shown to have clear apoptotic activity in Mia Paca-2 cells, whereas TRAIL released after 1 day had a negligible activity. Finally, PEG-TRAIL PLGA MS displayed remarkably greater antitumor efficacy than blank or TRAIL PLGA MS in Mia Paca-2 cell-xenografted mice in terms of tumor volume and weight, apparently due to increased stability and well-retained apoptotic activity of PEG-TRAIL in PLGA MS. We believe that this PLGA MS system, combined with PEG-TRAIL, should be considered a promising candidate for treating pancreatic cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Byeon

Kim

Choi

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Doxorubicin-conjugated HSA nanoparticles coated with TRAIL (TRAIL/Dox HSA NP) were fabricated using a modification of previously described procedures [11,28,29]. Briefly, an aliquot (3.2 ml) of doxorubicin (Dox) hydrochloride (1 mg/ml) in 50 mM phosphate buffer (PB; pH 8.0) was thiolated by adding 0.8 ml of 2-iminothiolane (Traut's reagent: 1.6 mg, 2 equiv.…”

Section: Preparation Of Doxorubicin-conjugated Hsa-np With Adsorbed Tmentioning

confidence: 99%

Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer

Choi

Byeon

Choi

et al. 2015

Journal of Controlled Release

Self Cite

135

View full text Add to dashboard Cite

“…The results revealed that antitumor activity of TRAIL in mice xenografted with Mia Paca-2 was remarkably higher because of stability of PEGylated TRAIL in HA hydrogels (Byeon et al, 2014). Bae et al (2012) designed human serum albumin (HSA) nanoparticles with the surface modified by TRAIL and transferrin, and containing doxorubicin, which were demonstrated to have a significant in vitro killing activity against different cancer cell lines. Among these cells, the authors studied the cytotoxic and apoptotic activities of the nanoparticles on CAPAN-1, a metastatic pancreatic cancer cell line.…”

Section: The Role Of Nanotechnology On Antitumor Activity Of Trailmentioning

confidence: 99%

TRAIL Mediated Signaling in Pancreatic Cancer

Nogueira

Yaylım²,

Aamir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Research over the years has progressively shown substantial broadening of the tumor necrosis factor alpharelated apoptosis-inducing ligand (TRAIL)-mediated signaling landscape. Increasingly it is being realized that pancreatic cancer is a multifaceted and genomically complex disease. Suppression of tumor suppressors, overexpression of oncogenes, epigenetic silencing, and loss of apoptosis are some of the extensively studied underlying mechanisms. Rapidly accumulating in vitro and in vivo evidence has started to shed light on the resistance mechanisms in pancreatic cancer cells. More interestingly a recent research has opened new horizons of miRNA regulation by DR5 in pancreatic cancer cells. It has been shown that DR5 interacts with the core microprocessor components Drosha and DGCR8, thus impairing processing of primary let-7. Xenografting DR5 silenced pancreatic cancer cells in SCID-mice indicated that there was notable suppression of tumor growth. There is a paradigm shift in our current understanding of TRAIL mediated signaling in pancreatic cancer cells that is now adding new layers of concepts into the existing scientific evidence. In this review we have attempted to provide an overview of recent advances in TRAIL mediated signaling in pancreatic cancer as evidenced byfindings of in vitro and in vivo analyses. Furthermore, we discuss nanotechnological advances with emphasis on PEG-TRAIL and four-arm PEG cross-linked hyaluronic acid (HA) hydrogels to improve availability of TRAIL at target sites.

show abstract

Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types

Cited by 215 publications

References 39 publications

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer

TRAIL Mediated Signaling in Pancreatic Cancer

Contact Info

Product

Resources

About